![post-main-image-Hospitalization as a Reachable Moment for Patients with Opioid Use Disorder](https://cherishresearch.org/wp-content/uploads/2021/08/post-main-image-Hospitalization-as-a-Reachable-Moment-for-Patients-with-Opioid-Use-Disorder-380x330.jpg)
Hospitalization as a Reachable Moment for Patients with Opioid Use Disorder
Imagine a medication that reduces morbidity and mortality from a disease that affects more than two million people in the United States. The medication drastically improves quality of life for those who take it and reduces costs to the health care system. For hospitalized patients, this medication decreases the chance of being readmitted and of […]
![post-main-onuoha-economic-evaluations](https://cherishresearch.org/wp-content/uploads/2023/03/post-main-onuoha-economic-evaluations-380x330.png)
Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review
In this systematic review, researchers affiliated with the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) including CHERISH staff Erica Onuoha and Jared Leff; CHERISH investigators Bruce R. Schackman, Kathryn E. McCollister, and Sean M. Murphy; and CHERISH Advisory Board member Daniel Polsky, identified new studies supporting buprenorphine and methadone as economically advantageous medications for […]
![post-main-image-Harmonizing Healthcare and Other Resource Measures (1)](https://cherishresearch.org/wp-content/uploads/2021/04/post-main-image-Harmonizing-Healthcare-and-Other-Resource-Measures-1-380x330.jpg)
Harmonizing Healthcare and Other Resource Measures for Evaluating Economic Costs in Substance Use Disorder Research
The National Institute on Drug Abuse, or NIDA, considers data harmonization in substance use disorder, human immunodeficiency virus (HIV), and hepatitis C virus (HCV) research a high-priority. Data harmonization allows investigators to synthesize data across independent studies and promote more rigorous and comparable analyses of an intervention, program, or policy. Harmonizing data also ensures that […]
![investigators-murphy-sean](https://cherishresearch.org/wp-content/uploads/2023/03/investigators-murphy-sean-380x330.jpg)
Healthcare utilization patterns among persons who use drugs during the COVID-19 pandemic
The COVID-19 pandemic has changed the way individuals access the healthcare system. For example, recent studies suggest high-risk populations may be foregoing necessary care out of fear of entering healthcare facilities and contracting the virus. A new study by Sean Murphy, PhD, associate professor of population health sciences at Weill Cornell Medicine and director of the methodology core […]
![post-main-cost-of-OUD](https://cherishresearch.org/wp-content/uploads/2023/04/post-main-cost-of-OUD-380x330.jpg)
The Cost of Opioid Use Disorder and the Value of Aversion
According to a new study, the total annual cost of opioid use disorder (OUD) to U.S. society in 2018 was $786.8 billion. This figure includes costs associated with excess healthcare expenditures, criminal justice resources, lost workplace and home productivity, and premature mortality. Of the $786.8 billion, $89.1 billion was attributed to additional healthcare expenditures. The study […]
![post-main-rapid-versus-lab-testing](https://cherishresearch.org/wp-content/uploads/2020/10/post-main-rapid-versus-lab-testing-380x330.jpg)
Rapid versus Laboratory HIV and HCV testing for People Who Use Drugs
HIV outbreaks in Indiana, West Virginia, and Massachusetts have highlighted the need to rapidly identify and treat HIV infections among people who use drugs and their social networks in order to prevent disease transmission. Many state and local health departments have expanded their fourth generation laboratory-based HIV testing capacity that allows them to identify acute […]
![post-main-effects-of-COVID19-on-SSP](https://cherishresearch.org/wp-content/uploads/2023/04/post-main-effects-of-COVID19-on-SSP-380x330.jpg)
Effects of COVID-19 on Syringe Service Programs
They have increased prevalence of pre-existing co-morbidities that may increase their risk of a negative outcome following COVID-19 exposure, for example respiratory and cardiovascular diseases due to smoking cigarettes, marijuana, or other substances. Syringe service programs (SSPs) not only provide sterile injection equipment to PWUD, but also other health services such as HIV and hepatitis C […]
![post-main-image-physician-survey-a](https://cherishresearch.org/wp-content/uploads/2023/04/post-main-image-physician-survey-a-380x330.jpg)
Starting Opioid Use Disorder Treatment in the Emergency Department: Physician-reported barriers and facilitators
Every day, we hear about the staggering toll of the opioid overdose crisis. This is particularly salient in Philadelphia, which has one of the highest overdose death rates among major U.S. cities. Despite effective medications for opioid use disorder, such as buprenorphine and methadone, few people receive treatment. The ongoing challenge is to expand access to these lifesaving treatments […]
![post-main-cost-effectiveness-of-XR-NTX](https://cherishresearch.org/wp-content/uploads/2022/08/post-main-cost-effectiveness-of-XR-NTX-380x330.png)
Criminal Justice Measures for Economic Data Harmonization in Substance Use Disorder Research
The intersection of criminal justice-involved populations and people who use substances makes criminal justice outcomes particularly significant for estimating the economic impact of substance use disorder interventions. New National Institute on Drug Abuse (NIDA) HEAL initiative funding opportunities in response to the opioid crisis include integrated studies that will develop, test, and validate evidence-based approaches to preventing […]
![post-main-image-2018-cpdd-sean-kathryn](https://cherishresearch.org/wp-content/uploads/2018/04/post-main-image-2018-cpdd-sean-kathryn-380x330.jpg)
Cost and Cost-Effective Analyses of Buprenorphine Naloxone versus Injectable Naltrexone
One key strategy in reducing deaths from the opioid epidemic is to improve access to existing evidence-based treatments. Two new economic studies by CHERISH Investigators Drs. Sean Murphy, Kathryn McCollister, and Bruce Schackman can help providers, patients, and payers sort through alternative pharmacotherapies to prevent opioid relapse. The US Food and Drug Administration has approved […]
![post-main-image-2018-Economic Evaluation Training in March](https://cherishresearch.org/wp-content/uploads/2018/04/post-main-image-2018-Economic-Evaluation-Training-in-March-380x330.jpg)
CHERISH Hosts Introduction to Economic Evaluation Training in March
On March 19, researchers from institutions across the country joined CHERISH leaders Bruce Schackman, Kathryn McCollister, Benjamin Linas and Sean Murphy for a daylong CHERISH introductory training to economic evaluations. Dr. Schackman began the day by introducing CHERISH to the attendees, who represented more than 25 institutions across New England, the Midwest, the Mid-Atlantic, the South […]
![post-main-image-kathryn-mccollister-mcf-blog](https://cherishresearch.org/wp-content/uploads/2023/04/post-main-image-kathryn-mccollister-mcf-blog-380x330.jpg)
Monetary Conversion Factors for Evaluating Substance Use Disorder Interventions: New Resource for Researchers
The National Institute on Drug Abuse estimates that substance use disorders, comprising illicit drugs and alcohol use as well as smoking, cost the United States more than $740 billion per year. This includes the cost of crime, incarceration, lost productivity, and medical care. A recent study considered the economic consequences of heroin use specifically, finding […]
Engage with CHERISH
Submit a Consultation Request or Contact Us to learn more about how CHERISH can support your research or policy goals.